08/01/2025  17:30:06 Chg. -0.88 Volume Bid21:02:53 Demandez à21:02:53 Capitalisation boursière Dividende Y. Rapport P/E
76.34CHF -1.14% 788,556
Chiffrre d'affaires: 60.35 Mio.
76.02Bid taille: 120 -Ask la taille: 439 37.97 Mrd.CHF - -

Description de l'entreprise

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, the company offers the broadest portfolio of products to enhance sight and improve people’s lives. Its Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. More than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
 

Conseil d'administration & Conseil de surveillance

PDG
David Endicott
Conseil d'administration
Tim Stonesifer, Ian Bell, Laurent Attias, Rajkumar Narayanan, Sergio Duplan, Sue-Jean Lin
Conseil de surveillance
F. Michael Ball, Arthur Cummings, D. Keith Grossman, David J. Endicott, Dieter Spälti, Ines Pöschel, Karen May, Lynn Bleil, Scott Maw, Thomas Glanzmann, Raquel C. Bono
 

Données de l'entreprise

Nom: Alcon Inc.
Adresse: Chemin de Blandonnet 8,CH-1214 Vernier, Geneva
Téléphone: +41-589-112-110
Fax: -
Courriel: investor.relations@alcon.com
Internet: https://www.alcon.com
Industrie: Healthcare
Secteur: Medical Products
Sous-secteur: Advanced Medical Devices
Fin de l'exercice financier: 31/12
Flotte libre: 98.64%
IPO date: 09/04/2019

Relations avec les investisseurs

Nom: Allen Trang
Téléphone IR: +41 589 112 110
IR-Fax: -
E-mail IR: investor.relations@alcon.com

Calendrier de l'entreprise

CW 9 | 26/02/2025 Report 4th Quarter
CW 19 | 06/05/2025 General Shareholder Meeting
CW 20 | 14/05/2025 Interim Report 1st Quarter/3 Months
CW 34 | 20/08/2025 Interim Report 2nd Quarter/6 Months
CW 46 | 12/11/2025 Interim Report 3rd Quarter/9 Months
 

Principaux actionnaires

Autres
 
79.08%
Cede & Co
 
20.92%